Cantor Believes Alnylam Is In 'Breakout Mode,' Sees Recent Strength From 2 Factors: 1. Greater Confidence That RNAi Is A Real New Class Of Commercial Medicines, 2. Less Concern Pfizer's Tafamidis Will Take Meaningful Share From Onpattro Launch